Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
8.45
-0.54 (-6.01%)
At close: Feb 21, 2025, 4:00 PM
8.44
-0.01 (-0.12%)
After-hours: Feb 21, 2025, 6:54 PM EST
Indivior Employees
Indivior had 1,164 employees as of December 31, 2023. The number of employees increased by 236 or 25.43% compared to the previous year.
Employees
1,164
Change (1Y)
236
Growth (1Y)
25.43%
Revenue / Employee
$1,020,619
Profits / Employee
-$41,237
Market Cap
1.08B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
INDV News
- 2 days ago - Indivior PLC (INDV) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat - Benzinga
- 2 days ago - UK's Indivior forecasts 17% decline in 2025 revenue - Reuters
- 2 days ago - Indivior Announces FY and Q4 2024 Financial Results - PRNewsWire
- 10 days ago - Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes - PRNewsWire
- 3 months ago - Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 - PRNewsWire
- 3 months ago - Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior - PRNewsWire
- 4 months ago - Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month - PRNewsWire